Related Experiment Video
Updated: Jan 1, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Knockdown of long noncoding RNA DLX6-AS1 inhibits migration and invasion of thyroid cancer cells by upregulating UPF1
1Department of Head and Neck Cancer Radiation Therapy, Harbin Medical University Cancer Hospital, Harbin, China. gexiaofeng121@163.com.
Objective:
Recently, long non- coding RNAs (lncRNAs) have attracted much attention for their roles in tumor progression. The aim of this study was to investigate the exact role of lncRNA DLX6 antisense RNA 1 (DLX6-AS1) in the development of thyroid cancer (TC), and to explore the underlying mechanism.
Patients And Methods:
DLX6-AS1 expression in both TC cells and tissue samples was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Moreover, transwell assay and wound healing assay were conducted. QRT-PCR and Western blot assay were used to explore the underlying mechanism. Furthermore, the function of DLX6-AS1 was identified in vivo.
Results:
DLX6-AS1 expression level in TC tissues was significantly higher than that of the corresponding normal tissues. Moreover, TC cell migration and invasion were markedly inhibited after DLX6-AS1 was knocked down in vitro. The mRNA and protein expressions of UPF1 were both remarkably up-regulated after knockdown of DLX6-AS1. Meanwhile, the expression level of UPF1 was negatively correlated with the expression of DLX6-AS1 in TC tissues. Furthermore, knockdown of DLX6-AS1 significantly inhibited tumor metastasis in vivo.
Conclusions:
Knockdown of DLX6-AS1 could inhibit TC cell migration and invasion via upregulating UPF1, which might be a potential therapeutic target in TC.
Insights
Long non-coding RNA DLX6-AS1 promotes thyroid cancer (TC) progression. Inhibiting DLX6-AS1 suppresses TC cell migration and invasion by upregulating UPF1, suggesting DLX6-AS1 as a potential therapeutic target.
Area of Science:
- Molecular Biology
- Oncology
- RNA Biology
Background:
- Long non-coding RNAs (lncRNAs) are increasingly recognized for their critical roles in cancer development.
- The specific involvement of lncRNA DLX6 antisense RNA 1 (DLX6-AS1) in thyroid cancer (TC) pathogenesis requires further elucidation.
Purpose of the Study:
- To investigate the role of DLX6-AS1 in thyroid cancer progression.
- To explore the underlying molecular mechanisms by which DLX6-AS1 influences TC development.
Main Methods:
- Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) to assess DLX6-AS1 expression in TC tissues and cells.
- In vitro assays (Transwell, wound healing) to evaluate cell migration and invasion.
- Western blot to analyze protein expression, including UPF1.
- In vivo studies to confirm the functional role of DLX6-AS1 in tumor metastasis.
Main Results:
- DLX6-AS1 expression was significantly elevated in TC tissues compared to normal tissues.
- Knockdown of DLX6-AS1 inhibited TC cell migration and invasion in vitro.
- DLX6-AS1 knockdown led to increased mRNA and protein expression of UPF1.
- UPF1 expression was negatively correlated with DLX6-AS1 levels in TC tissues.
- In vivo, DLX6-AS1 knockdown significantly suppressed tumor metastasis.
Conclusions:
- DLX6-AS1 promotes thyroid cancer progression by enhancing cell migration and invasion.
- The mechanism involves the downregulation of UPF1.
- Targeting DLX6-AS1 represents a potential therapeutic strategy for thyroid cancer.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
MicroRNAs
MicroRNAs
Experimental RNAi
Non-LTR Retrotransposons

